{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Posaconazole&page=2", "query": { "intervention": "Posaconazole", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Posaconazole&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-20T23:19:29.157Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Samalizumab (BAML-16-001-S1)", "type": "BIOLOGICAL" }, { "name": "BI 836858 (BAML-16-001-S2)", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Daunorubicin (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S2)", "type": "DRUG" }, { "name": "AG-221 (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Daunorubicin (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Pevonedistat (BAML-16-001-S9)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S9)", "type": "DRUG" }, { "name": "AG-120 (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "AZD5153 (BAML-16-001-S10)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S10)", "type": "DRUG" }, { "name": "TP-0903 (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "AZD5991 (BAML-16-001-S18)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S18)", "type": "DRUG" }, { "name": "SNDX-5613 (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 1)", "type": "DRUG" }, { "name": "ficlatuzumab (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S24)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 2)", "type": "DRUG" }, { "name": "Bleximenib (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Revumenib (BAML-16-001-S26/HO177)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S26/HO177)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Beat AML, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2016-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-20T23:19:29.157Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013998" }, { "nct_id": "NCT07780565", "title": "Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Monzosertib", "type": "DRUG" }, { "name": "Posaconazole", "type": "DRUG" }, { "name": "Isavuconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2027-01-01", "completion_date": "2031-08-30", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-20T23:19:29.157Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07780565" }, { "nct_id": "NCT07261150", "title": "Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Histoplasmosis" ], "interventions": [ { "name": "LAmB B", "type": "DRUG" }, { "name": "Posaconazole", "type": "DRUG" }, { "name": "World Health Organization (WHO)-recommended SOC", "type": "DRUG" }, { "name": "WHO-recommended SOC Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 664, "start_date": "2026-10-01", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-20T23:19:29.157Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07261150" }, { "nct_id": "NCT07155226", "title": "Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukaemia", "Acute Myeloid Leukaemia", "Higher-risk Myelodysplastic Syndromes" ], "interventions": [ { "name": "AZD3632", "type": "DRUG" }, { "name": "Posaconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 84, "start_date": "2026-01-09", "completion_date": "2029-02-15", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-20T23:19:29.157Z", "location_count": 6, "location_summary": "Decatur, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Decatur", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07155226" }, { "nct_id": "NCT02358499", "title": "Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fungal Infections" ], "interventions": [ { "name": "Posaconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Mercy Hospital Kansas City", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 31, "start_date": "2015-01", "completion_date": "2018-12-31", "has_results": false, "last_update_posted_date": "2020-12-22", "last_synced_at": "2026-09-20T23:19:29.157Z", "location_count": 1, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02358499" }, { "nct_id": "NCT07044544", "title": "Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloid Malignancy", "Hematologic Malignancy", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "G-CSF", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2025-07-17", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-09-20T23:19:29.157Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07044544" }, { "nct_id": "NCT03614455", "title": "Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pharmacokinetics" ], "interventions": [ { "name": "Milademetan", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Posaconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2018-07-13", "completion_date": "2018-10-01", "has_results": false, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-09-20T23:19:29.157Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03614455" }, { "nct_id": "NCT06129734", "title": "Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloid Malignancy", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Benjamin Tomlinson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-07-28", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-09-20T23:19:29.157Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06129734" }, { "nct_id": "NCT00002446", "title": "Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Candidiasis, Oral", "HIV Infections" ], "interventions": [ { "name": "Posaconazole", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Schering-Plough", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "1998-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-20T23:19:29.157Z", "location_count": 17, "location_summary": "Berkeley, California • San Francisco, California • Denver, Colorado + 13 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002446" }, { "nct_id": "NCT00750737", "title": "Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Invasive Fungal Infections", "Hematologic Malignancies" ], "interventions": [ { "name": "Posaconazole", "type": "DRUG" }, { "name": "ABLC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2008-06", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2016-09-29", "last_synced_at": "2026-09-20T23:19:29.157Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00750737" } ] }